MedTrace Logo

Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI)

NCT01312935 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2012-05-17

No results posted yet for this study

Summary

The study investigates the safety and efficacy of PMX-60056 for the Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI)

Conditions

  • Percutaneous Coronary Intervention
  • Coronary Artery Disease (CAD)
  • Angioplasty

Interventions

DRUG

PMX-60056

investigational drug

Sponsors & Collaborators

  • PolyMedix, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2012-06-30
Completion
2012-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01312935 on ClinicalTrials.gov